• KinATLAS
  • TranscriptoNET
  • PhosphoNET
  • OncoNET
  • KinaseNET
  • DrugKiNET
  • DrugProNET
  • KiNET-AM
  • Kinetica Online

Updated November 2019

Home | Kinexus | Contact | Credits

Nomenclature

Short Name:
LKB1
Full Name:
Serine-threonine-protein kinase 11
Alias:
  • AMPKK
  • EC 2.7.11.1
  • KPM
  • PJS
  • Renal carcinoma antigen NY-REN-19
  • STK11

Classification

Type:
Protein-serine/threonine kinase
Group:
CAMK
Family:
CAMKL
SubFamily:
LKB
 
 

Specific Links

BioCarta Entry: intrinsic pathway
Entrez-Gene Entry: 6794
Entrez-Protein Entry: NP_000446
GeneCards Entry: LKB1
KinBASE Entry: LKB1
OMIM Entry: 602216
Pfam Entry: Q15831
PhosphoNET Entry: Q15831
Phosphosite Plus Entry: 617
ScanSite Entry: Q15831
Source Entry: STK11
UCSD-Nature Entry: A003018
UniProt Entry: Q15831
Kinexus Products: LKB1
Serine/threonine-protein kinase 11 pan-specific antibody AB-NK227-1
Serine/threonine-protein kinase 11 pan-specific antibody AB-NK227-2
Serine/threonine-protein kinase 11 pan-specific antibody AB-NK227-2P
Serine/threonine-protein kinase 11 pan-specific antibody AB-NK227-3
Serine/threonine-protein kinase 11 pan-specific antibody AB-NK227-4
Serine/threonine-protein kinase 11 S31 phosphosite-specific antibody AB-PK682
Serine/threonine-protein kinase 11 S428 phosphosite-specific antibody AB-PK683
Serine/threonine-protein kinase 11 (M1-G15, human) peptide - Powder PE-01ASN99
Serine/threonine-protein kinase 11 (M1-G15, human) peptide - Powder PE-01ASN99
Serine/threonine-protein kinase 11 (L85-I99, human) peptide - Powder PE-01ASO90
Serine/threonine-protein kinase 11 (L85-I99, human) peptide - Powder PE-01ASO90
Serine/threonine-protein kinase 11 (A295-F309, human) peptide - Powder PE-01ASP90
LKBSubtide - LKB1 (STK11) protein kinase substrate peptide - Powder PE-01BHW90
Serine/threonine-protein kinase 11 (R28-V34, human) pS31 phosphopeptide - Powder PE-04ANJ99
Serine/threonine-protein kinase 11 (R425-K431, human) pS428 phosphopeptide - Powder PE-04ANK95

General Links

ClustalW2
GPS-Cuckoo
Human Protein Atlas
Kinase.com
Kinase Research
Kinasource
Kinomer
Netphorest
NetworKIN
Phosida
PhosphoElm
Protein Blast
ScanSite
String

Structure

Mol. Mass (Da):
48,636
# Amino Acids:
433
# mRNA Isoforms:
2
mRNA Isoforms:
48,636 Da (433 AA; Q15831); 45,387 Da (404 AA; Q15831-2)
4D Structure:
Found in a ternary complex composed of SMAD4, STK11 and STK11IP. Interacts with SMAD4, STK11IP and WDR6.
1D Structure:
Retrieve Gene Sequence
Retrieve Full Protein Sequence
Retrieve Catalytic Domain Sequence
 
3D Image (rendered using PV Viewer):

PDB ID
2WTK

Subfamily Alignment
subfamily domain
 
Domain Distribution:
Start End Domain
49 309 Pkinase
 

Kinexus Products

Click on entries below for direct links to relevant products from Kinexus for this protein kinase.
hiddentext
○ Serine/threonine-protein kinase 11 pan-specific antibody AB-NK227-1
○ Serine/threonine-protein kinase 11 pan-specific antibody AB-NK227-2
○ Serine/threonine-protein kinase 11 pan-specific antibody AB-NK227-2P
○ Serine/threonine-protein kinase 11 pan-specific antibody AB-NK227-3
○ Serine/threonine-protein kinase 11 pan-specific antibody AB-NK227-4
○ Serine/threonine-protein kinase 11 S31 phosphosite-specific antibody AB-PK682
○ Serine/threonine-protein kinase 11 S428 phosphosite-specific antibody AB-PK683
○ Serine/threonine-protein kinase 11 (M1-G15, human) peptide - Powder PE-01ASN99
○ Serine/threonine-protein kinase 11 (M1-G15, human) peptide - Powder PE-01ASN99
○ Serine/threonine-protein kinase 11 (L85-I99, human) peptide - Powder PE-01ASO90
○ Serine/threonine-protein kinase 11 (L85-I99, human) peptide - Powder PE-01ASO90
○ Serine/threonine-protein kinase 11 (A295-F309, human) peptide - Powder PE-01ASP90
○ LKBSubtide - LKB1 (STK11) protein kinase substrate peptide - Powder PE-01BHW90
○ Serine/threonine-protein kinase 11 (R28-V34, human) pS31 phosphopeptide - Powder PE-04ANJ99
○ Serine/threonine-protein kinase 11 (R425-K431, human) pS428 phosphopeptide - Powder PE-04ANK95
 

Post-translation Modifications

For detailed information on phosphorylation of this kinase go to PhosphoNET
Acetylated:
K44 (N6), K48 (N6), K96 (N6), K97 (N6), K296 (N6), K311 (N6), K416 (N6), K423 (N6), K431 (N6).
Methylated:
C430 (predicted).
Other:
C430 (S-farnesyl cysteine, predicted).
Palmitoylated:
C418 (predicted).
Serine phosphorylated:

S31, S240, S307, S334, S401, S428+.
Threonine phosphorylated:

T32, T185+, T189, T336-, T363+, T402+.
Tyrosine phosphorylated:

Y36, Y60, Y156, Y166.
 

Distribution

Based on gene microarray analysis from the NCBI
Human Tissue Distribution
% Max Expression:

Mean Expression:

Number of Samples:

Standard Deviation:
% Max Expression:

Mean Expression:

Number of Samples:

Standard Deviation:
  • adipose
    55

    969

    41

    1077

  • adrenal
    5

    89

    16

    102

  • bladder
    34

    597

    11

    454

  • brain
    17

    307

    134

    472

  • breast
    43

    770

    44

    550

  • cervix
    6

    110

    100

    287

  • colon
    9

    158

    51

    409

  • heart
    39

    688

    38

    652

  • intestine
    10

    182

    17

    149

  • kidney
    7

    129

    132

    183

  • liver
    14

    252

    32

    299

  • lung
    44

    783

    174

    634

  • lymphnode
    15

    270

    33

    362

  • ovary
    3

    51

    9

    74

  • pancreas
    20

    353

    25

    529

  • pituitary
    5

    90

    25

    76

  • prostate
    8

    151

    125

    176

  • salivarygland
    17

    303

    19

    309

  • skeletalmuscle"
    11

    199

    122

    241

  • skin
    29

    510

    165

    473

  • spinalcord
    16

    280

    24

    314

  • spleen
    16

    286

    28

    290

  • stomach
    32

    561

    13

    416

  • testis
    31

    549

    20

    441

  • thymus
    20

    356

    22

    378

  • thyroid
    48

    855

    84

    588

  • tonsil
    10

    174

    36

    238

  • trachea
    20

    364

    20

    450

  • uterus
    21

    379

    20

    411

  • reticulocytes"
    28

    501

    56

    604

  • t-lymphocytes
    41

    732

    24

    677

  • b-lymphocytes
    100

    1777

    46

    3580

  • neutrophils
    15

    265

    95

    718

  • macrophages
    45

    798

    104

    665

  • sperm
    11

    188

    61

    289

 

Evolution

Species Conservation
PhosphoNET % Identity:
PhosphoNET % Similarity:
Homologene %
Identity:
PhosphoNET % Identity:
PhosphoNET % Similarity:
Homologene %
Identity:
  • tableheader
    100

    100

    100
  • tableheader
    99.3

    99.3

    99
  • tableheader
    99.3

    99.5

    99
  • tableheader
    -

    -

    98
  • tableheader
    -

    -

    93
  • tableheader
    92.5

    94.5

    93.5
  • tableheader
    -

    -

    -
  • tableheader
    90.1

    93.3

    91
  • tableheader
    90.6

    93.1

    91
  • tableheader
    -

    -

    -
  • tableheader
    57.7

    63.3

    -
  • tableheader
    89.3

    93.2

    90.5
  • tableheader
    81.3

    87.5

    84
  • tableheader
    82.3

    87.3

    83
  • tableheader
    -

    -

    -
  • tableheader
    41.5

    54.9

    53
  • tableheader
    54.6

    71.9

    -
  • tableheader
    29.8

    43.8

    43
  • tableheader
    57.7

    72.3

    -
  • tableheader
    -

    -

    -
  • tableheader
    -

    -

    -
  • tableheader
    -

    -

    -
  • tableheader
    27.5

    43.7

    -
  • tableheader
    -

    -

    -
  • tableheader
    -

    -

    -
For a wider analysis go to PhosphoNET Evolution in PhosphoNET
 

Binding Proteins

Examples of known interacting proteins
hiddentext
No. Name – UniProt ID
1 STRADA - Q7RTN6
2 CAB39 - Q9Y376
3 PRKAA2 - P54646
4 PTEN - P60484
5 TP53 - P04637
6 WDR6 - Q9NNW5
7 HSP90AA2 - Q14568
8 TNIP2 - Q8NFZ5
9 CDC37 - Q16543
10 SMARCA4 - P51532
11 MARK2 - Q7KZI7
12 HSP90AA1 - P07900
13 MARK1 - Q9P0L2
14 RPS6KB1 - P23443
15 RPS6KA3 - P51812
 

Regulation

Activation:
Activated by binding of a complex consisting of CAB39 and STRAD or CAB39 and ALS2CR2. Phosphorylation at Ser-307 induces interaction with AMPK1, STLK5 and exportin 1. Phosphorylation at Ser-428 increases phosphotransferase activity.
Inhibition:
Phosphorylation at Thr-336 inhibits LKB1.
Synthesis:
NA
Degradation:
NA
 

Known Upstream Kinases

For further details on these substrates click on the Substrate Short Name or UniProt ID. Phosphosite Location is hyperlinked to PhosphoNET predictions.
Based on in vitro and/or in vivo phosphorylation data

Kinase Short Name UniProt ID (Human) Phosphosite Location Phosphosite Sequence Effect of Phosphorylation
LKB1 Q15831 T189 LLLTTGGTLKISDLG ?
PKCz Q05513 S307 IRQIRQHSWFRKKHP ?
LKB1 Q15831 T336 KDRWRSMTVVPYLED +
ATM Q13315 T363 IEDDIIYTQDFTVPG +
LKB1 Q15831 T363 IEDDIIYTQDFTVPG +
DNAPK P78527 T363 IEDGIIYTQDFTVPG +
PKACa P17612 S428 SSKIRRLSACKQQ__ +
MSK1 O75582 S428 SSKIRRLSACKQQ__ +
p70S6K P23443 S428 SSKIRRLSACKQQ__ +
PKCz Q05513 S428 SSKIRRLSACKQQ__ +
LKB1 Q15831 S428 SSKIRRLSACKQQ__ +
RSK1 Q15418 S428 SSKIRRLSACKQQ__ +
DNAPK P78527 S428 SSKIRRLSACKQQ__ +
 

Known Downstream Substrates

For further details on these substrates click on the Substrate Short Name or UniProt ID. Phosphosite Location is hyperlinked to PhosphoNET predictions.
Based on in vitro and/or in vivo phosphorylation data

Substrate Short Name UniProt ID (Human) Phosphosite Location Phosphosite Sequence Effect of Phosphorylation
AMPKa1 (PRKAA1) Q13131 S496 ATPQRSGSVSNYRSC
AMPKa1 (PRKAA1) Q13131 T183 SDGEFLRTSCGSPNY +
AMPKa1 (PRKAA1) Q13131 T269 VDPMKRATIKDIREH +
AMPKa2 (PRKAA2) P54646 S491 STPQRSCSAAGLHRP
AMPKa2 (PRKAA2) P54646 T172 SDGEFLRTSCGSPNY +
AMPKa2 (PRKAA2) P54646 T258 VDPLKRATIKDIREH
BRSK1 Q8TDC3 T189 VGDSLLETSCGSPHY +
BRSK2 Q8IWQ3 T174 VGDSLLETSCGSPHY +
LKB1 (STK11) Q15831 S428 SSKIRRLSACKQQ__ +
LKB1 (STK11) Q15831 T189 LLLTTGGTLKISDLG ?
LKB1 (STK11) Q15831 T336 KDRWRSMTVVPYLED +
LKB1 (STK11) Q15831 T363 IEDDIIYTQDFTVPG +
MARK1 Q9P0L2 T215 TVGNKLDTFCGSPPY +
MARK2 Q7KZI7 T208 TFGNKLDTFCGSPPY +
MARK3 P27448 S215 KLDTFCGSPPYAAPE -
MARK3 P27448 S238 KLDTFCGSPPYAAPE -
MARK3 P27448 T211 TVGGKLDTFCGSPPY +
MARK3 P27448 T234 TVGGKLDTFCGSPPY +
MARK4 Q96L34 T214 TLGSKLDTFCGSPPY +
MELK Q14680 T167 NKDYHLQTCCGSLAY +
NuaK1 (ARK5) O60285 T211 QKDKFLQTFCGSPLY +
Nuak2 Q9H093 S573 PPLRGCVSVDNLTGL
Nuak2 Q9H093 T208 HQGKFLQTFCGSPLY +
Nuak2 Q9H093 Y131 KIVIVMEYASRGDLY
p53 P04637 S15 PSVEPPLSQETFSDL +
p53 P04637 S392 FKTEGPDSD______ +
PTEN P60484 S380 EPDHYRYSDTTDSDP -
PTEN P60484 T382 DHYRYSDTTDSDPEN -
PTEN P60484 T383 HYRYSDTTDSDPENE -
QIK (SIK2) Q9H0K1 T175 KSGELLATWCGSPPY +
QSK Q9Y2K2 T163 TPGQLLKTWCGSPPY +
SIK P57059 T182 KSGEPLSTWCGSPPY +
SNRK Q9NRH2 T173 QPGKKLTTSCGSLAY +
STRADA (STRAD) Q7RTN6 T329 GLSDSLTTSTPRPSN
STRADA (STRAD) Q7RTN6 T419 SGIFGLVTNLEELEV
 

Protein Kinase Specificity

Matrix of observed frequency (%) of amino acids in aligned protein substrate phosphosites

Kinections GIF
Matrix Type:
Experimentally derived from alignment of 51 known protein substrate phosphosites.
Domain #:
1
 

Inhibitors

For further details on these inhibitors click on the Compound Name and enter it into DrugKiNET or click on the ID's
Based on in vitro and/or in vivo phosphorylation data
Compound Name KD, Ki or IC50 (nM) PubChem ID ChEMBL ID PubMed ID
IKK-2 Inhibitor IV Kd < 10 nM 9903786 257167 19035792
Tozasertib Kd < 10 nM 5494449 572878 19035792
Nintedanib Kd = 18 nM 9809715 502835 22037378
Sunitinib Kd = 38 nM 5329102 535 18183025
IDR E804 IC50 > 50 nM 6419764 1802727 22037377
PKR Inhibitor IC50 > 50 nM 6490494 235641 22037377
TWS119 IC50 > 50 nM 9549289 405759 22037377
Lestaurtinib Kd = 57 nM 126565 22037378
Staurosporine Kd = 61 nM 5279 18183025
PP242 IC50 < 80 nM 25243800
AT9283 IC50 > 100 nM 24905142 19143567
TTT-3002 IC50 = 100 nM
AC1NS4N8 Kd < 150 nM 23649240 19035792
Cdk1/2 Inhibitor III IC50 > 150 nM 5330812 261720 22037377
Indirubin-3′-monoxime IC50 > 150 nM 5326739 22037377
KW2449 Kd = 240 nM 11427553 1908397 22037378
Aloisine A IC50 > 250 nM 5326843 75680 22037377
Gö6976 IC50 > 250 nM 3501 302449 22037377
GSK-3 Inhibitor IX IC50 > 250 nM 5287844 409450 22037377
JAK3 Inhibitor VI IC50 > 250 nM 16760524 22037377
K-252a; Nocardiopsis sp. IC50 > 250 nM 3813 281948 22037377
TBCA IC50 > 250 nM 1095828 22037377
AZ960 IC50 < 300 nM 25099184 18775810
TG101348 Kd = 310 nM 16722836 1287853 22037378
N-Benzoylstaurosporine Kd = 350 nM 56603681 608533 18183025
SU14813 Kd = 360 nM 10138259 1721885 18183025
LKB1(AAK1 dual inhibitor) Kd = 380 nM 44588117 516312 19035792
Hesperadin Kd < 400 nM 10142586 514409 19035792
Staurosporine aglycone IC50 < 400 nM 3035817 281948
1;9-Pyrazoloanthrone IC50 = 500 nM 8515 7064 22037377
AG-E-60384 IC50 = 500 nM 6419741 413188 22037377
PP1 Analog II; 1NM-PP1 IC50 = 500 nM 5154691 573578 22037377
RGB-286147 IC50 = 500 nM 9549301 258721 22037377
SB218078 IC50 = 500 nM 447446 289422 22037377
SU9516 IC50 = 500 nM 5289419 258805 22037377
Syk Inhibitor II IC50 = 500 nM 16760670 22037377
BCP9000906 IC50 > 1 µM 5494425 21156 22037377
GDC-0941 IC50 = 1 µM 17755052 521851
GSK-3 Inhibitor XIII IC50 > 1 µM 6419766 359482 22037377
GSK429286 IC50 = 1 µM 11373846 375312
H-1152; Glycyl IC50 = 1 µM 16760635
Icotinib IC50 > 1 µM 22024915 22112293
IPA-3 IC50 = 1 µM 521106 472940
MK5108 IC50 > 1 µM 24748204 20053775
Purvalanol A IC50 = 1 µM 456214 23327
Purvalanol B IC50 = 1 µM 448991 23254
R406 IC50 = 1 µM 11984591
Silmitasertib IC50 > 1 µM 24748573 21174434
SNS314 IC50 > 1 µM 16047143 514582 18678489
Syk Inhibitor IC50 > 1 µM 6419747 104279 22037377
WZ3146 Kd > 1 µM 44607360 20033049
WZ4002 Kd > 1 µM 44607530 20033049
AC1O6ZUA Kd < 1.25 µM 6539569 408019 19035792
SureCN373973 Kd < 1.25 µM 9818573 30678 19035792
Princeton's TrkA inhibitor compound 20h IC50 < 2 µM
PHA-665752 Kd = 2.6 µM 10461815 450786 22037378
(5Z)-7-Oxozeaenol IC50 > 3 µM 1077979
BMS-690514 Kd < 3 µM 11349170 21531814
BX795 IC50 > 3 µM 10077147 577784
Dovitinib Kd = 3.7 µM 57336746 18183025
JNJ-28871063 IC50 > 4 µM 17747413 17975007
Amgen TBK 1 inhibitor (Compound II) IC50 > 4.5 µM
BI-78D3 IC50 > 4.5 µM 2747117 508280
 

Disease Linkage

General Disease Association:

Cancer, gastrointestinal disorders
Specific Diseases (Non-cancerous):

Peutz-Jeghers syndrome; Intussusception; Tuberous sclerosis; Cowden disease; Juvenile polyposis syndrome; Polyhydramnios; Megalencephaly
Comments:
Peutz-Jeghers syndrome (PJS) is an autosomal-dominant disease characterized by polyp formation in the gastrointestinal tract and abnormal pigment deposition on the lips, buccal muccosa, and digits. PJS is associated with an increased risk for gastrointestinal and pancreatic cancer. Intussusception is a gastrointestinal disease realted to PJS. Cowden syndrome is a genetic disease characterized by the formation of numerous non-cancerous growths (hamartomas) on various areas of the body, which is associated with an increased risk of developing breast, thyroid, or endometrial cancer. Several mutations in the LKB1 gene have been observed in patients with PJS, including a deletion mutation of exons 4 and 5, an inversion of exons 6 and 7, terminal mutations (Y253X, K84X, E57X, Y246X), a 1-bp deletion at 843G resulting in a frameshift, a 4-bp deletion (716delGGTC) causing a frameshift, a splice site mutation causing a frameshift, substitution mutations (L67P, G135R, W239C, F354L), and a 9-bp deletion mutation converting the 4 codons from 303-309 from ile-arg-gln-his to a single asn. All of the mutations associated with the disease lead to inactivation of the LKB1 protein. For example, the substitution mutations are located in highly conserved residues in the kinase catalytic domain. It has been estimated that germline inactivating mutations in the LKB1 gene account for 60% of familial and 50% of sporadic cases of PJS. In addition, ~42% of patients with PJS do not display mutations in LKB1, indicating the involvement of other genes in the disease pathology. Several of the observed mutations in the LKB1 gene are predicted to disrupt the interation between LKB1 and PTEN. PTEN is a dual phosphatase that is routinely mutated in autosomal disorders with similar phenotypes as PJS (e.g. Cowden syndrome), indicating a role for LKB1/PTEN interaction in the disease pathogenesis and confirming LKB1 as a key tumour suppressor in intestinal cells.
 
Specific Cancer Types:
Pancreatic cancer; Lung cancer; Carney complex; Acinar cell carcinomas; Large cell carcinomas; Germ cell tumours; Testicular tumours, somatic; Melanomas, malignant, somatic; Male germ cell tumours, somatic; Spermatocytic seminomas, somatic
Comments:
LKB1 appears to be a tumour suppressor protein (TSP). Cancer-related mutations in human tumours point to a loss of function of the protein kinase. The active form of the protein kinase normally acts to promote tumour cell proliferation. Mutations in the LKB1 gene have been observed in cancer patients. In particularly, cancer-associated mutations are found in the substrate recognition domain of the protein or result in protein truncation. Whereas, mutations affecting ATP binding and catalysis are rarely observed in human cancer. Significantly reduced LKB1 expression has been observed in benign intestinal polyps, correlated with reduced apoptosis. This is thought to be the cause of the aberrant growth and may potentially contribute to the development of malignant intestinal tumours. Additionally, LKB1 protein in tumour cells is restricted to the nucleus, compared to the normal distribution of the protein in both the nucleus and cytoplasm. The introduction of LKB1 protein into LKB1-deficient cancer cell lines results in G1 phase cell cycle arrest. This effect is still seen for LKB1 proteins that lack nuclear localization signals, indicating that the tumour suppressive effects of the kinase are mediated in the cytoplasm. The proposed mechanism of LKB1-mediated cell cycle arrest is a p53-dependent induction of p21. In animal studies, LKB1-deficient tumours displyed shorter latency, an expanded histological prolife (including adeno-, squamous-, and large cell carcinoma), as well as more frequent metastasis when compared to tumours lacking p53 or Arf (other tumour suppressor genes). In addition, LKB1 inactivation was observed in 34% of adenocarcinomas and 19% of squamous cell carcinomas in 144 human lung cancer specimens. Analysis of gene expression in human lung cancer cell lines and mouse lung tumours revealed that repression of LKB1 results in the activation of various metastasis-promoting genes, such as NEDD9, VEGFC, and CD24. Therefore, it has been concluded that LKB1 is a key cellular component in the prevention of pulmonary tumorigenesis and in the control of initiation, differentiation, and metastasis of lung cancer cells.
 
Gene Expression in Cancers:

TranscriptoNET (www.transcriptonet.ca) analysis with mRNA expression data retrieved from the National Center for Biotechnology Information's Gene Expression Omnibus (GEO) database, which was normalized against 60 abundantly and commonly found proteins, indicated altered expression for this protein kinase as shown here as the percent change from normal tissue controls (%CFC) as supported with the Student T-test in the following types of human cancers: Breast epithelial cell carcinomas (%CFC= +65, p<0.003); and Skin melanomas - malignant (%CFC= +83, p<0.004). The COSMIC website notes an up-regulated expression score for LKB1 in diverse human cancers of 391, which is 0.9-fold of the average score of 462 for the human protein kinases. The down-regulated expression score of 196 for this protein kinase in human cancers was 3.3-fold of the average score of 60 for the human protein kinases.
Mutagenesis Experiments:

Insertional mutagenesis studies in mice support a role for this protein kinase in mouse cancer oncogenesis.
Mutation Rate in All Cancers:

Percent mutation rates per 100 amino acids length in human cancers: 0.33 % in 31881 diverse cancer specimens. This rate is 4.5-fold higher than the average rate of 0.075 % calculated for human protein kinases in general.
Mutation Rate in Specific Cancers:

Highest percent mutation rates per 100 amino acids length in human cancers: 1.45 % in 460 cervix cancers tested; 1.38 % in 4085 lung cancers tested; 0.83 % in 1771 large intestine cancers tested; 0.63 % in 1083 skin cancers tested; 0.32 % in 999 stomach cancers tested; 0.2 % in 1491 pancreas cancers tested.
Frequency of Mutated Sites:

Most frequent mutations with the number of reports indicated in brackets: F354L (36); D194Y (12); P281L (11).
Comments:
Over 50 deletions, 20 insertions and 6 complex mutations are noted on the COSMIC website.
 
COSMIC Entry:
STK11
OMIM Entry:
602216
  • Home
  • Top of Page
Copyright 2019 Kinexus BioInformatics Corporation